Serotonin-selective reuptake inhibitors (SSRIs) remain the frontline treatment for many mood disorders. The other major class of serotonergic (5-HT) antidepressants targets the serotonin 1A (5-HT1A) receptor. The delayed onset and the ϳ60% response rate of these drugs for many patients leave a need for additional therapies to accelerate the onset of therapeutic action (1-3). The membrane bound receptors, ion channels, and transporters expressed by the 5-HT neurons are good drug candidates to specifically modulate 5-HT neuronal activity. While our recent studies suggest that central nervous system (CNS) neurons may express up to 300 -500 different receptors and that the transcriptome and the proteome of CNS neurons correlate with each other (4, 5), currently only a small portion of the receptors (ϳ20 -30) expressed in the 5-HT neurons of the dorsal raphe (DR) have been identified (6, 7). An attempt to document a large number of ion channels expressed by midbrain neurons has recently been performed using the Allen Institute's Brain Atlas; however, this approach assesses only selected genes and does not allow for the distinction between serotonergic and nonserotonergic cells in the DR (8). Also, the sensitivity of large in situ hybridization (ISH) screens is far lower than that of single-cell analysis. Such a search for all known G-protein-coupled receptors (GPCRs), which are often easily druggable membrane proteins, would be daunting and of limited use without knowledge of the neurochemical identity of the neurons in which they reside.
Serotonin-selective reuptake inhibitors (SSRIs) remain the frontline treatment for many mood disorders. The other major class of serotonergic (5-HT) antidepressants targets the serotonin 1A (5-HT1A) receptor. The delayed onset and the ϳ60% response rate of these drugs for many patients leave a need for additional therapies to accelerate the onset of therapeutic action (1) (2) (3) . The membrane bound receptors, ion channels, and transporters expressed by the 5-HT neurons are good drug candidates to specifically modulate 5-HT neuronal activity. While our recent studies suggest that central nervous system (CNS) neurons may express up to 300 -500 different receptors and that the transcriptome and the proteome of CNS neurons correlate with each other (4, 5) , currently only a small portion of the receptors (ϳ20 -30) expressed in the 5-HT neurons of the dorsal raphe (DR) have been identified (6, 7) . An attempt to document a large number of ion channels expressed by midbrain neurons has recently been performed using the Allen Institute's Brain Atlas; however, this approach assesses only selected genes and does not allow for the distinction between serotonergic and nonserotonergic cells in the DR (8) . Also, the sensitivity of large in situ hybridization (ISH) screens is far lower than that of single-cell analysis. Such a search for all known G-protein-coupled receptors (GPCRs), which are often easily druggable membrane proteins, would be daunting and of limited use without knowledge of the neurochemical identity of the neurons in which they reside.
The DR has multiple distinct subregions that develop efferant and afferent pathways with differing regions. The lateral wings (LWs) are located just ventrolateral to the cerebral aqueduct in the midbrain. This region has strong connections with the centrolateral periaqueductal gray and rostral ventrolateral medulla, and these interactions are thought to be central to anxiety phenotypes (9) . The ventrolateral DR is located directly 1 These authors contributed equally to this work. 2 Correspondence: University of Pennsylvania, 37 John Morgan Bldg., 3620 Hamilton Walk, Philadelphia, PA 19104, USA. E-mail: eberwine@upenn.edu doi: 10.1096/fj.13-240267
Abbreviations: 5-CT, 5-carboxyamidotryptamine; 5-HT, serotonergic; 5-HT1A, serotonin 1A; Adra1a, adrenergic 1a receptor; aRNA, antisense RNA; CNS, central nervous system; DR, dorsal raphe; GPCR, G-protein-coupled receptor; H3, histamine 3; ISH, in situ hybridization; Lpar1, lysophosphatidic acid receptor 1; LW, lateral wing; Oxtr, oxytocin receptor; PE, phenylephrine; RMP: resting membrane potential; SSRI, serotonin-selective reuptake inhibitor; TTX, tetrodotoxin; VM, ventromedial; YFP, yellow fluorescent protein ventral to the aqueduct and has known connections with the hypothalamus, locus coeruleus, and many other brain regions (10, 11) . Pet-1 is an ETS domain transcription factor and is a stable marker specific to 5-HT neurons (12) . A transgenic mouse line was utilized that expresses yellow fluorescent protein (YFP) driven by the Pet-1 promoter (13), thereby rendering 5-HT neurons fluorescent and allowing us to harvest and analyze single 5-HT neurons.
Beginning with single-cell sequencing, we elucidated a list of potentially therapeutically useful GPCR mRNAs present in 5-HT neurons, demonstrated subregional variation in 5-HT neuronal GPCR mRNA content, and showed functional verification for the presence and activity of a subset of these receptors. Specifically, we show the functional protein expression of lysophosphatidic acid receptor 1 (Lpar1) and oxytocin receptor (Oxtr) in 5-HT neurons. We also report that the histamine 3 (H3) receptor is the target of the earlier documented histaminergic inhibition of 5-HT signaling (14) and that its antagonism can cause increased excitability in 5-HT neurons. Lastly, combinations of agonists and antagonists to these novel receptors on 5-HT neurons in concert with agonists to previously known receptors can exert additive effects on neuronal activity. This account of expressed GPCR mRNAs, especially the several dozen orphan GPCRs that we have shown to be present in 5-HT neurons, represents a novel resource to those studying 5-HT signaling and also provides pharmacologic potential for modulating DR neurons that have been shown to be dysregulated in multiple mood disorders (15) .
MATERIALS AND METHODS

Animals
Embryonic day 18 (E18) C57/BL6 mice and transgenic adult (Ͼ3 mo) male mice expressing YFP driven by the 5-HT neuron specific Pet-1 promoter (ePet-1::YFP) were used (13) . This transgenic mouse line has been backcrossed Ն10 generations to the C57BL6 strain in our laboratory. All mice were housed in a standard animal facility with a 12-h light-dark cycle. All animals were used in accordance with the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals, and all experiments were approved by the Institutional Animal Care and Use Committee at the Children's Hospital of Philadelphia Research Institute.
Transcriptomics data analysis
Acute slices from P60 ePet-YFP animals (7, 13) were perfused with artificial cerebral spinal fluid (aCSF; in mM: 124 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 2.0 MgSO 4 , 2.5 CaCl 2 , 10 dextrose, and 26 NaHCO 3 ) bubbled with 95% O 2 /5% CO 2 . Patch electrodes were pulled as described previously (7), filed with a minimal amount of first-strand buffer, and advanced toward each YFP-positive neuron. Positive pressure was applied until the tip was next to the cell. Slight negative pressure was then applied until the cellular contents were aspirated into the pipette. These cellular contents were immediately processed for linear antisense RNA (aRNA) amplification (16) . Following 3 rounds of linear amplification of the RNA populations and sequencing of RNA libraries using the RNA Truseq reagents from Illumina (San Diego, CA, USA), the reads were aligned as described previously (17) . Briefly, reads were aligned using Bowtie against the genome and transcriptome. Mapped reads were combined and unmapped reads were aligned using BLAT against the genome and merged with the earlier mapped reads. Only mapped reads (as defined by aligning to only 1 location with Ͻ3 mismatches/100 bases) were used in further analysis. The features (intronic, exonic reads) were quantified and only exonic reads were included in this analysis. Reads were normalized using the Bioconductor package DESeq (http://www.bioconductor.org; ref. 18 For the comparison of DR neurons with neurons of other brain regions, hippocampal and cortical cultures were generated from E18 C57/BL6 mouse pups and were maintained for 2 wk in culture as described previously (22) . Single pyramidal neurons were harvested by pipette aspiration, and the RNA population was amplified using the same amplification protocols as was followed for the 5-HT neurons.
A Wilcoxon rank-sum test was used with a null hypothesis of zero location shift and an alternative hypothesis of a nonzero location shift, after prefiltering genes to include only those with Ն50 reads in some sample. Heatmaps were generated in R using the heatmap.2 method of the gplots library (23, 24) . The differential expression heatmap depicts log counts after range normalization and zero centering. Most and least variable genes were selected based on the coefficient of variation, estimated using normalized counts. Heatmap visualization uses the log of normalized counts.
Electrophysiology
Electrophysiology recordings were conducted as described previously (7, 25) . In brief, ePet-YFP mice were killed using decapitation. The midbrain was rapidly dissected and blocked while submerged in cold aCSF solution where NaCl was replaced with sucrose (248 mM), and cut with a Leica VT1000s vibratome (Leica Microsystems, Bannockburn, IL, USA) to generate 200-m-thick brain slices. Slices were maintained in a holding chamber containing aCSF and bubbled with 95%O 2 /5%CO 2 at 36°C for 1 h and then at room temperature until used. Tryptophan (5 M) was included in the holding chamber to maintain 5-HT synthesis before recording.
Individual slices were then placed in a recording chamber and continuously perfused with 32-34°C aCSF solution bubbled with 95%O 2 /5%CO 2 with a solution flow rate of 1.5-2.0 ml/min. Neurons were visualized using a Nikon E600 (Optical Apparatus, Ardmore, PA, USA) upright microscope fitted with a ϫ40 water-immersion objective, DIC, and infrared filter. LW 5-HT neurons were targeted based on topographical expression of YFP. To visualize YFP-positive 5-HT cells for recording, a fluorescent lamp and yellow-fluorescence filter were used. The image from the microscope was enhanced using a CCD camera and displayed on a monitor. e-Pet-5-HT neurons were visualized under fluorescence and targeted under DIC (Optical Apparatus). Whole-cell recording pipettes fabricated on a Sutter Instruments pipette puller (P-97; Sutter Instruments, Novato, CA, USA) had a resistance of 6 -10 M⍀ when filled with an intracellular solution of 130 mM K-gluconate, 5 mM NaCl, 10 mM Na-phosphocreatinine, 1 mM MgCl 2 , 0.02 mM EGTA, 10 mM HEPES, 2 mM MgATP, 0.5 mM Na 2 GTP, and 0.1% biocytin (pH 7.3). Voltage-clamp recordings were conducted at a holding potential of Ϫ60 mV. Recordings were collected online with a Multiclamp 700B amplifier, Digidata 1320 A/D converter, and Clampex 9.0 software (Molecular Devices, Union City, CA, USA). Membrane properties of the cell were monitored, as was the access resistance of the patch pipette during recordings that lasted a minimum of 20 min. Recordings were discarded if access resistance increased Ͼ5 times the initial access resistance noted before patching onto the cell. Reported values do not incorporate a junction potential of approximately ϩ15 mV, as calculated using Clampex software. 
Drug treatments
Electrophysiology data analysis
Current-clamp recordings using visualized whole-cell patchclamp techniques were analyzed using Clampfit 9.0 (Molecular Devices). Resting membrane potential (RMP) and membrane resistance were measured as described previously (7) . Membrane input resistance was determined from the slope of voltage-current plot generated using current pulses ranging from Ϫ100 to 0 pA. Firing rate was calculated using MiniAnalysis program (Synaptosoft, Decatur, GA, USA).
RESULTS
Transcriptomics analysis
As the subregions of the DR project to influence the neural activity of differing forebrain regions associated with multiple mood disorders (9, 26) , and have distinct physiological characteristics (7, 25) , we harvested single 5-HT neurons from 2 subregions of the DR: the LW and the ventromedial (VM; Fig. 1A ; nϭ10/subregion). Using a transgenic mouse line that expresses YFP driven by the Pet-1 promoter, thereby rendering 5-HT neurons fluorescent (13), we harvested the intracellular contents of single 5-HT neurons from live midbrain slices in vitro (Fig. 1B) . The RNA populations from these cells were processed through 3 rounds of linear aRNA amplification (16, 27) and subjected to Illumina RNA sequencing analysis. Each of the cells had Ն2 ϫ 10 7 reads mapping back to the mouse genome when analyzed using the RUM mapping program (17) . To mitigate differences in read depth across samples, counts were normalized using the method proposed by Anders and Huber (18) . The variation of GPCR expression between the 2 regions of the DR was examined. Focusing on genes that were expressed in Ն1 cell at 50 normalized reads or more, we identified the genes that were differentially expressed between the LW and VM (having a value of PϽ0.01 uncorrected). The expression of these 57 genes across all 20 cells was then visualized in a heatmap, highlighting the differing profiles of these subregions ( Fig. 2A , left 20 columns). To illustrate the selectivity of these profiles to the different types of 5-HT neurons, the expression profiles of the DR cells were compared with those of cortical and hippocampal pyramidal neurons ( Fig. 2A, right 16 columns). While the expression patterns for many of these genes are different between cortical and hippocampal neurons, the expression patterns for both hippocampal and cortical neurons were distinct from those of the DR 5-HT neurons. Next, we identified the 500 most and least variable genes across all cells of each cell type (1829 unique genes total). There were genes represented at all expression levels that were found to be both variant and invariant suggesting the unique phenotype of each cell was dependent on its unique intercellular connections (Fig. 2B) .
Among the identified mRNAs were those encoding several proteins previously shown to be present in 5-HT neurons, including Pet-1, tryptophan hydroxylase, the 5-HT1A receptor, and multiple subtypes of adrenoreceptors. This study focuses on the expression of the highly druggable GPCRs, although NextGen sequencing of these 20 5-HT neurons provided us with a list of all expressed mRNAs encoding other classes of proteins. The distribution of expressed genes (as defined by the GO database; ref. 28) was similar between the LW and VM Raphe neurons, with 2% identified as GPCRs, 2% as ion channels, and 8% as enzymes. Among the 391 GPCRs encoding RNAs in the LW and 344 in the VM that were identified, many receptor mRNAs were highly and/or differentially expressed between the 2 regions (Fig. 3) . Normalized read counts Ͻ1 were the result of normalizing the reads in 1 cell to the read depth of all the samples. Any count Ͼ0 represents a uniquely mapped expressed transcript, while a count of Ͻ1 means that the sample had much lower expression relative to the read coverage for all of the other genes in all samples. Figure 3 shows the presence of mRNAs encoding classical neurotransmitters, such as noradrenaline, histamine, serotonin, and GABA; neuropeptides, such as neuropeptide Y (NPY), cholecystokinin (CCK), hypocritine, oxytocin, melanocortin, somatostatin, and substance P (SP); and receptors for lipid mediators, such as lysophosphatidic acid and spinghosine-1 phosphate; as well as a large number of orphan GPCRs and olfactory receptors. The frequency of expression for some of these GPCRs is high; i.e., many of the examined 20 neurons expressed them. In all cells, there were many olfactory receptor mRNAs expressed, and although the natural ligands for these receptors are unknown, this represents an interesting observation different from what has been observed in olfactory neurons (29, 30) . The H3 receptor was present in 8 of 10 LW neurons and 6 of 10 VM neurons; Lpar1 was present in 11 of 20 neurons tested; and Oxtr was present in 8 of 20 tested neurons (at mostly low read counts, 0.2-301.42 normalized reads/cell). The variability in mRNA expression between cells was in line with what has previously been observed in other cell types, as well, and was thought to result in part from a unique combination of inputs to each individual cell (5). These 3 GPCR receptor types: a classical neurotransmitter receptor (H3 receptor), a lipid signal receptor (Lpar1), and a peptide receptor (Oxtr), respectively, were chosen for the proof of concept functional experiments due to their expression in multiple cells and to the availability of selective pharmacological agents that target the receptors, respectively.
Functional verification of the translation of Oxtr, Lpar1, and H3 receptor
We functionally validated the single-cell transcriptomeidentified GPCRs (Oxtr, Lpar1, and H3 receptor), employing whole-cell electrophysiological techniques in brain slices. YFP-positive 5-HT neurons in the LW were identified in acute slices and patched. Receptor agonists were used at concentrations similar to those found in the literature to show that these mRNAs identified through the transcriptome analysis were indeed present as functional signaling proteins. R-␣-methylhistamine (H3 agonist) is a very potent, highaffinity H3 agonist (K d ϭ50.3 nM) that displays Ͼ200-fold selectivity over H4 receptors and has limited activity at H1 (0.5% of histamine response) and H2 (1% of histamine response) receptors (Tocris; ref. 10; Fig. 4A ). Only 2 of 10 neurons exhibited an outward current (25Ϯ15 pA, avgϮsd for outwardly responding population). Both responses, inward and outward currents, were maintained in the presence of tetrodotoxin (TTX; 1 M) to block presynaptic activity (Fig. 4B) . Bath application of oxytocin (3-10 M; refs. 33, 34) , elicited a response in 6 of 22 cells tested, with 4 showing a very pronounced inward current (85.8Ϯ8.0 pA) and 2 exhibiting an outward current (118.5Ϯ44.7 pA; Fig. 4C) . Last, the Lpar1 receptor was evaluated.
The Lpar1 agonist NAEPA is most active at Lpar1, although it has limited activity at Lpar2 (35) . However, in our transcriptome study, we found very low expression of Lpar2 in 20% of LW cells, so this should not be a major confounder. NAEPA (30 M; refs. 36, 37) elicited an inward current in 5 of 7 cells (Ϫ14.7Ϯ3.59 pA; Fig. 4D ), which was inhibited by the Lpar1-selective antagonist, Ki-16245.
To determine whether the novel GPCRs receptors and the earlier well-known 5-HT neuronal modulators, ␣1A adrenergic, and 5-HT1A receptors of the 5 HT neurons shared receptor-effector cascades that would manifest in interactions of the effects of these receptor agonists, we measured the effects of drugs in combination. First, we combined the H3 agonist methylhistamine with a 5-HT1A agonist, 5-carboxyamidotryptamine (5-CT), and found opposing responses (Fig. 5A) . Phenylephrine is an adrenergic 1A (Adra1a) receptor agonist frequently used to induce the normal endogenous firing rate of 5-HT neurons in the brain slice (7). When methylhistamine was tested in the presence of 3 M phenylephrine (PE) using current-clamp recording techniques, the primary response was a decrease in F2r, F2rl1, F2rl2, Ffar2, Ffar3 , Fpr2, Fzd3, Fzd5, Fzd7, Gabbr1, Gabbr2, Glp2r, Gpr108, Gpr111, Gpr116, Gpr12, Gpr123, Gpr124, Gpr126, Gpr132, Gpr133, Gpr137, Gpr146, Gpr15, Gpr152, Gpr155, Gpr157, Gpr158, Gpr160, Gpr162, Gpr176, Gpr180, Gpr19, Gpr22, Gpr25, Gpr26, Gpr3, Gpr37l1, Gpr4, Gpr56, Gpr63, Gpr68, Gpr75, Gpr77, Gpr84, Gpr85, Gpr88, Gpr89, Gpr98, Gprc5b, Gprc5c, Grm1, Grm5, Grm8, Hcrtr1, Hcrtr2, Hrh1, Hrh3, Htr1a, Htr1b, Htr2a, Htr2c, Htr5a, Htr6, Igf2r, Kiss1r, Lgr4, Lgr5, Lpar1, Lpar2, Lpar3, Lpar4, Lphn1, Lphn2, Lphn3, Mc1r, Mchr1, Mrgpra4, Mrgprb1, Mrgprb3, Mrgpre, Mrgprg, Nmur2, Npffr1, Npy1r, Ntsr2, Opn1mw, Opn3, Oprd1, Oprl1, Oxgr1, Oxtr, Ptgfr, Pthr1, S1pr1, S1pr4, S1pr5, Sctr, Tacr1, Tas1r3, Uts2r, Vmn2r105, Vmn2r113, Vmn2r24, Vmn2r27, Vmn2r35, Vmn2r39, Vmn2r55, Vmn2r6
Dorsal Raphe Lateral Wing Pet-eYFP 5-HT single neurons DRL_1
Adcyap1r1, Adora1, Adra1a, Adra1b, Adra2a, Adra2b, Adra2c, Adrb2, Agtr2, Bai1, Bai2, Bai3, C3ar1, Calcr, Ccr2, Ccr5, Celsr1, Celsr2, Celsr3, Chrm1, Chrm2, Cnr1, Crhr1, Cx3cr1, Cxcr2, Ednrb, Eltd1, Emr1,
DRL_3
Adcyap1r1, Adora1, Adra1a, Adra1b, Adra2b, Avpr1a, Bai1, Bai2, Bai3, C3ar1, Calcr, Calcrl, Cckbr, Ccr2, Ccr3, Ccr4, Ccr6, Ccr9, Ccrl2, Cd97, Celsr2, Celsr3, Chrm1, Chrm4, Cnr1, Cxcr2, Cxcr7, Drd2, Ednrb, Eltd1, F2r, F2rl3, Fpr2, Fzd10, Fzd3, Gabbr1, Gabbr2, Gpr107, Gpr108, Gpr110, Gpr12, Gpr123, Gpr126, Gpr137, Gpr146, Gpr149, Gpr152, Gpr153, Gpr155, Gpr157, Gpr158, Gpr160, Gpr162, Gpr165, Gpr17, Gpr174, Gpr176, Gpr180, Gpr19, Gpr22, Gpr25, Gpr26, Gpr3, Gpr37l1, Gpr4, Gpr56, Gpr62, Gpr64, Gpr68, Gpr77, Gpr85, Gpr88, Gpr89, Gpr98, Gprc5b, Gprc5c, Grm1, Grm3, Grm4, Grm5, Grm7, Grm8, Hcrtr1, Hrh3, Htr1a, Htr1b, Htr1d, Htr1f, Htr2a, Htr2c, Htr5a, Htr6, Igf2r, Lgr4, Lgr5, Lpar1, Lphn1, Lphn2, Lphn3, Mas1, Mc1r, Mrgprb5, Mrgpre, Npy1r, Npy2r, Ntsr2, Opn3, Opn4, Oprl1, P2ry10, P2ry12, Prokr2, Ptgfr, Pthr1, Rgr, Rxfp2, S1pr4, S1pr5, Sctr, Sstr1, Tacr1, Tas1r3, Vmn1r127, Vmn2r106, Vmn2r120, Vmn2r121, Vmn2r2, Vmn2r23, Vmn2r32, Vmn2r52, Vmn2r55, Vmn2r66, Vmn2r73, Vmn2r78, Xcr1
Dorsal Raphe Ventromedial Pet-eYFP 5-HT single neurons DRV_3
Adcyap1r1, Adora1, Adra1b, Adra2a, Adra2b, Adra2c, Adrb1, Adrb2, Avpr1b, Bai1, Bai2, Bai3, C3ar1, C5ar1, Calcr, Cckar, Ccr4, Ccr9, Celsr1, Celsr2, Celsr3, Chrm1, Chrm4, Cmklr1, Cnr1, Cnr2, Cx3cr1, Cxcr2, Drd1a, Drd2, Drd3, Drd5, Ednrb, F2r, F2rl1, F2rl3, Ffar2, Fpr2, Fzd10, Fzd3, Fzd4, Fzd5, Fzd6, Gabbr1, Gabbr2, Glp2r, Gnrhr, Gpr101, Gpr107, Gpr108, Gpr110, Gpr116, Gpr123, Gpr126, Gpr137, Gpr149, Gpr150, Gpr152, Gpr156, Gpr157, Gpr158, Gpr160, Gpr162, Gpr165, Gpr171, Gpr173, Gpr174, Gpr176, Gpr180, Gpr19, Gpr21, Gpr26, Gpr3, Gpr35, Gpr37l1, Gpr4, Gpr56, Gpr64, Gpr68, Gpr75, Gpr77, Gpr83, Gpr85, Gpr88, Gpr89, Gpr98, Gprc5b, Gprc5c, Grm1, Grm3, Grm5, Grm7, Grm8, Hcrtr1, Hcrtr2, Hrh3, Htr1a, Htr1b, Htr1d, Htr2c, Htr5a, Htr5b, Igf2r, Lgr4, Lgr5, Lpar1, Lpar3, Lphn1, Lphn2, Lphn3, Mc1r, Mchr1, Mrgprb1, Mrgpre, Nmur2, Npffr1, Npffr2, Npy1r, Npy2r, Ntsr2, Opn3, Opn4, Opn5, Oprl1, Oxtr, P2ry1, P2ry12, P2ry4, Prokr2, Ptger2, Ptger4, Ptgfr, Ptgir, Pthr1, Qrfpr, Rgr, Rho, S1pr1, S1pr4, S1pr5, Smo, Sstr2, Tacr1, Tas2r143, Vipr2, Vmn1r51, Vmn2r109, Vmn2r120, Vmn2r23, Vmn2r25, Vmn2r33, Vmn2r55, Vmn2r82, Xcr1 DRV_4 Adcyap1r1, Adora1, Adra1a, Adra1b, Adra2b, Adrb2, Adrb3, Bai3, C3ar1, C5ar1, Calcr, Ccr2, Ccr4, Celsr2, Chrm4, Cmklr1, Cnr1, Cx3cr1, Cxcr2, Cxcr4, Ednrb, F2r, Ffar2, Fzd3, Fzd5, Gabbr1, Gabbr2, Gpr107, Gpr108, Gpr116, Gpr137c, Gpr157, Gpr160, Gpr162, Gpr171, Gpr174, Gpr176, Gpr180, Gpr19, Gpr26, Gpr3, Gpr39, Gpr4, Gpr56, Gpr62, Gpr68, Gpr77, Gpr97, Gprc5c, Grm1, Grm3, Grm8, Hcrtr1, Hrh3, Htr1a, Htr1b, Htr1d, Htr2a, Htr6, Igf2r, Lgr4, Lgr5, Lpar1, Lphn1, Lphn3, Mc1r, Mchr1, Mrgprb1, Mrgpre, Mrgprg, Nmur2, Oprl1, P2ry12, P2ry4, P2ry6, Ptgdr, Pthr1, S1pr4, S1pr5, Sstr2, Tacr1, Tas2r131, Tbxa2r, Vmn2r55, Vmn2r85 firing rate. Bath application of methylhistamine (30 -100 M) showed an opposing effect to that of PE and decreased PE induced excitability in 8 of 13 neurons tested (1.67Ϯ1.6 vs. 0.41Ϯ2.3 Hz, paired t test, Pϭ0.0064; Fig. 5B ). Iodophenpropit is a selective H3 antagonist with high affinity that does not significantly interact with the H1 or H2 receptors as measured with competition assays (38) . The response elicited by methylhistamine was blocked by the H3 receptor antagonist, iodophenpropit (3 M; ref. 39) . Oxytocin had a synergistic effect with PE and further increased the PEinduced firing rate of the 2 neurons that were tested (Fig. 5C) . Last, activation of the Lpar1 receptor by the selective agonist NAEPA produced an increase in the PE-induced firing activity of LW 5-HT neurons (2.24Ϯ0.94 Hz control vs. 3.09Ϯ0.88 Hz, paired t test Pϭ0.01 in 5 of 9 cells tested; Fig. 5D ).
Interestingly, when applied alone in the slice preparation, the H3 antagonist increased the firing rate induced by 3 M PE in the 3 serotonergic cells that were tested (Fig. 5E ). These data show that endogenous histamine is present in the extracellular medium in baseline conditions, suggesting that histamine acting through the H3 receptor tonically hyperpolarizes 5-HT neurons and once relieved of this inhibition, neuronal excitability is increased.
DISCUSSION
The 5-HT neurons of the DR are among the most studied neurons in the midbrain projecting to the forebrain due to their involvement in the physiology and pathophysiology of mood regulation, yet the receptors, transporters, and ion channels expressed by these important neurons are relatively unknown. This study providing characterization of GPCR mRNA expression from transcriptome analysis to functional verification is the first single-cell-based evaluation of genomics level receptor response capacity in 5-HT neurons. Due to the unprecedented sensitivity of sequencing-based singlecell transcriptomics, we have been able to identify hundreds of GPCR mRNAs that are transcribed in the LW and ventromedial DR and have verified multiple novel GPCRs that are translated into functional proteins and whose agonist stimulation alter excitability in 5-HT neurons of the DR. These and other GPCRs with known or yet unknown endogenous agonists (orphan GPCRs) may be valuable drug targets in development of novel antidepressant drugs acting alone or in combination with the drugs targeting 2 proteins on these neurons, the serotonin transporter and the 5-HT1A autoreceptor.
Single-cell sequencing in these subregions gives us unprecedented insight into the variety of expression profiles present in serotonergic neurons. In addition, we were able to investigate interregional differences by comparing the expression and variance between the DR subregions to that in cortical and hippocampal neurons. Looking at the differentially expressed genes, it is clear that 5-HT-classified neurons isolated from distinct subregions of the DR are unique, dependent on the region from which they are isolated. This is in line with previously observed differences in electrophysiology and protein expression between LW and VM 5-HT neurons (7, 25) . Specifically, one of the identified genes, Gad1, is also preferentially expressed in LW 5-HT neurons at the protein level (25) showing that this class of 5-HT neurons is also GABAergic. Examining the 500 highest-and lowest-ariability genes across all cells shows 4 distinct groupings (Fig.  2B) : both highly variable and invariant genes can be found at all expression levels. While invariant genes are likely essential for basic cell function (i.e., ribosomal, structural), variant genes may be responsive to a cell's unique input, recent history, and internal metabolic state (i.e., receptors, neurological systems process). While the invariant genes likely do not need to change based on each individual cells needs, the variant genes are presumptively controlled by each cell's input and output needs as they relate to the unique connections with efferent and afferent cells. The low vs. high expression in each of these groups may reflect differing resultant protein needs for proper signaling of each protein. This is supported by the fact that many highly expressed genes are variant and genes with low expression can be invariant. The grouping of the higher expressed genes in the low expression/high variance portion of Fig. 2B was a result of the clustering algorithm and not any one specific type of gene. In addition, these variability analyses show that while there are clear differences in expression between the two regions, individual cells, even within a given subregion, also show expression variability.
Our analyses of the GPCR mRNAs expressed suggest differing G-protein interactions and therefore differing dominant signaling pathways between the VM and LW. The functional significance of this apparent region specific difference in G-protein coupling is unclear and awaits more detailed information about the numbers and half-lives of translated GPCRs as well as other information. The predicted G-protein-coupling dichot- omy suggests that these two DR regions may be preferentially affected by pharmacology directed toward specific G-protein-associated classes of GPCRs. Investigation of candidate pathways highlighted by single-cell transcriptomics leading from GPCR to neuronal excitability, increases options from which to develop additive cotherapeutic strategies that could act synergistically through the same or different pathways, leading to a better (additive) and/or faster outcome. In support of this notion, our study has already shown that selected novel receptors are good candidates for therapeutic cotargeting, as their modulation led to an additive (with other common agonists for known 5-HT neuron localized receptors) increase in 5-HT neuron excitability.
The pharmacological evidence for the functional expression and for the robust physiological effects mediated by 3 different GPCRs that have not reported earlier on DR 5-HT neurons is that Oxtr, Lpar1, and the H3 receptor serve as examples that single-cell transcriptome analysis provides a way toward discovery of novel drug targets. Previous studies examining the distribution of some GPCRs in the DR had the same goal, to expand the set of drug targets through which 5-HT neuronal activity could be altered (40, 41) , but none have had the unbiased, all encompassing, singlecell resolution that is provided by single-cell RNA sequencing combined with single neuron functional validation using a transgenic mouse specifically highlighting 5-HT neurons. Our studies do not provide a thorough investigation into the mechanisms behind the receptor function or show the direct connection between activation of these receptors specifically on 5-HT neurons and behavior. However, we provide an extensive list of mRNAs encoding GPCRs expressed in the 5-HT neurons that were previously unknown, and we have confirmed that a subset of the receptors is translated and contributes directly to regulation of serotonergic neuron excitability. The data showing that in CNS neurons the transcriptome and the functional analysis correlate with each other suggests that one can target the effects exerted through many of the GPCRs whose mRNA we describe here, and thus one will be able to determine whether these GPCRs mediate a desirable and robust response that is of clinical significance in mood disorders.
Although we showed presence of the receptors and that they contribute to signaling of 5-HT neurons, the responses were not consistently in the same direction. For example, when oxytocin was used to stimulate the neurons, while we saw responses in 6 of 22 neurons tested, the currents were both inward and outward, depending on the cell. As we have shown, not all cells of a typically thought to be homogeneous population have identical transcriptomes and as a consequence, we hypothesize that there are subclasses within a brain subregion. The receptor may be differentially linking to effectors in distinct cells depending on the expression levels and/or phosphorylation states of the downstream signaling pathway components, thereby altering effector coupling after activation of the receptors. For example, the IUPHAR database states that Oxtr can couple to both G q and G i (21) , depending on the availability, proximity, and quantity of the G q and G i subunits (and other downstream effectors) in a given cell; hence, there may be a range of responses to an identical stimulation even with identical expression of the target receptor. This may underlie the variability we observed following receptor stimulation. Although additional experiments would need to be completed to confirm this explanation, the variability in expression of many second messenger genes identified only recently through the use of single-cell transcriptomics supports this hypothesis.
Oxytocin-containing hypothalamic neurons are known to project to the different nuclei of the forebrain, yet there are no reports on the Oxtr-mediated effects on DR 5-HT neurons as we show here. A previous report using an Oxtr-promoter-driven YFP variant suggested that Oxtr was expressed in a portion of 5-HT neurons of the median raphe and that oxytocin was anxiolytic when given intacerebroventricularly (42) . However, this experimental model did not detect Oxtr expression in the DR, demonstrating the improved sensitivity and reliability provided by single-cell sequencing over other techniques. The search for oxytocin agonists to treat autism and schizophrenia may also include effects on mood disorders, as we showed robust costimulation of 5-HT neurons via the ␣ 1 -adrenergic receptor and Oxtr. While Oxtr in humans is known to show polymorphism (43) that may relate to vulnerability in schizophrenia, we have not, in these rodent studies, noted presence of isoforms of Oxtr.
There are at least 3 isoforms of Lpar (44), mediating neurogenesis, neuroinflammation, necrosis, etc., and many of the Lpars are expressed in astroglia and in the vasculature. While our studies clearly show the functional expression of Lpar1 in 5-HT neurons, we have also shown the transcription of the other isoforms in the 5-HT neurons, and this represents a pharmacological opportunity to develop receptor subtype selective ligands for treatment of mood disorders through specific action on Lpar1 expressed by 5-HT neurons. The strong costimulatory effect of LPA on 5-HT neuron activity with ␣1 adrenoreceptor agonists provides cell specific information to the tissue-associated findings of a previous report showing that a complete Lpar1 knockout affected 5-HT release in in vitro brain slices (45) .
Histamine effects on 5-HT neuron firing (14, 46, 47) and H3 receptor ligand effects on anxiety behavior in rodents (48) have separately been previously reported. In 2000 and 2001, Sakai and Crochet (46, 47) identified histamine-mediated attenuation of sleep-induced cessation of firing of DR 5-HT neurons in awake and sleeping cats using extracellular recording. This H1-mediated increase in VM activity of cats is in contrast to the H3-mediated inhibition of whole-cell recorded activity that we observe in the mouse LW. As we have found much higher levels of H3 RNA expression in the LW, this suggests that LW 5-HT neuronal modulation by histamine is dominated by the H3 receptor and its effects on neuronal tone. Our findings therefore define the histamine response of the 5-HT LW neurons of the DR as directly mediated by the H3 receptor. This should shed light on a class of compounds, H3 antagonists, that are in clinical trials now for ADHD, epilepsy, and also for depression: some novel, dual acting drugs with 5-HT reuptake inhibitor-H3 antagonist profile are now entering clinical trials and our data show that part of their effects will be exerted at the DR 5-HT neurons.
Studies investigating the neurological effects of some of the agonists systemically targeting the identified receptors have been performed. Oxtr is well known for its role in the peripartum period of females (49) , and its activation has anxiolytic activity (42, 50) . H3 receptor has been shown previously to play a role in both anxiety and depression. Although the pharmacological literature is mixed, partly because of the lack of full receptor subtype selectivity of the agents used, it seems that antagonism of the H3 receptor can lead to both anxiolytic and antidepressive-like activity (51, 52) . Little has been done to investigate Lpar1 in the context of anxiety phenotypes, although a study showed that an Lpar1-knockout had increased anxiety-like behavior in 2 behavioral tests (53) . Currently, there is an incomplete picture of how these receptors exert their behavioral effects, and previously, there was no proof that these ligands could exert their functions directly on 5-HT neurons.
Our investigation into single-cell expression and variability of the receptors within 5-HT neurons of the DR provides insight into the complexity that underlies functioning of this neuronal population. Many attempts to find novel classes of antidepressants and other mood modulating drugs have met with less than desired success (3). This is due in part to an incomplete understanding of the signaling within the intended target cells. In this study, we show expression of a far greater number of receptor encoding genes whose activity all converge to create the cell's status/phenotype/excitability, etc. The complexity added by the varying responses to an agonist depending on the exact cell's receptor RNA and protein expression levels, ratios of receptors, and second messenger system component availability should not only be expected and appreciated but can also be exploited to develop drugs targeted to a better defined mechanism of action. Our data provide a rational blueprint for investigating the modulation of previously observed DR-mediated effects on behavior (9, 26) and encourage the development of several 5-HT neuron-targeting drugs. As the serotonergic neurons of the DR can be directly modulated with H3, Oxtr, and Lpar1, these receptors (and others revealed by this single-cell transcriptomics study) become putative drug candidates for modulating 5-HT neuronal activity in anxiety and depression. The observed H3-mediated endogenous control of 5-HT neurons regulating DR activity provides even more compelling evidence for H3 being a promising target for pharmacological intervention in mood disorders. These findings provide an extensive resource for neurobiological study into the function of the DR as well as many targets, which when used in concert with potentially lower levels of SSRI treatment may expedite relief of depressive symptoms while lessening their associated side effects.
